Apellis CEO Sells $592K in Stock to Cover RSU Taxes; Company Posts Slight FY2025 Revenue Miss
Apellis Pharmaceuticals Chief Executive Cedric Francois sold 27,192 shares on January 22, 2026, for $21.7654 per share, raising $591,844 to cover tax withholding on restricted stock units released a day earlier. The company reported preliminary U.S. product revenue for fiscal 2025 of $689 million, with revenue split between Syfovre and Empaveli, a …